de Romeuf C, Mazurier C
Laboratoire de Recherche sur l'Hémostase, Centre Régional de Transfusion Sanguine, Lille, France.
Thromb Haemost. 1993 May 3;69(5):436-40.
We developed a simple and fast method for studying the heparin binding of von Willebrand factor (vWF) in the plasma milieu. Using plasma from patients with von Willebrand disease (vWD) subtype II, we found that the heparin binding was impaired when compared with a normal plasma control. Further experiments performed with purified vWF of various multimeric composition, obtained either by gradual reduction or gel filtration, confirmed that heparin binding is dependent on the multimerization of vWF and that high molecular weight (HMW) multimers of vWF are required for normal heparin binding. After reduction of plasma vWF by 1.5 mM DTT, the vWF monomer still binds to heparin but to a lower extent. Under these conditions, no significant differences were obtained between control and patients showing that the heparin binding domain located on the vWF subunit is not altered in the subtypes IIA, IIB and IIC studied.
我们开发了一种简单快速的方法,用于研究血浆环境中血管性血友病因子(vWF)与肝素的结合。使用II型血管性血友病(vWD)患者的血浆,我们发现与正常血浆对照相比,肝素结合受损。对通过逐步还原或凝胶过滤获得的具有不同多聚体组成的纯化vWF进行的进一步实验证实,肝素结合取决于vWF的多聚化,并且正常的肝素结合需要vWF的高分子量(HMW)多聚体。用1.5 mM二硫苏糖醇(DTT)还原血浆vWF后,vWF单体仍与肝素结合,但程度较低。在这些条件下,对照和患者之间未获得显著差异,表明在所研究的IIA、IIB和IIC亚型中,位于vWF亚基上的肝素结合结构域未改变。